Based on McKenna & Towers
[1984]
Texts from Petrus
Pennanen, Michael from
Melbourne.
Huge amounts of HTML formatting and referencing by dimitri
dimitri@intac.com
Much of this document is available in other formats at
Hyperreal and Hyperspace
| Name of compound | R1 | R2 | R3 | R4 | R5 | Dosage (mg) | Route (Oral/Par) |
|---|---|---|---|---|---|---|---|
| tryptamine | H | H | H | H | H | 1001 | par/oral? |
| DMT (dimethyltryptamine) | CH3 | CH3 | H | H | H | 60 | par |
| DET | C2H5 | C2H5 | H | H | H | 60 | par/oral |
| DPT | n-prop | n-prop | H | H | H | 60 | par/oral |
| DAT | C3H5 | C3H5 | H | H | H | 30 | par/oral |
| DIPT | i-prop | i-prop | H | H | H | 30 | oral |
| 5-MeO-DIPT | i-prop | i-prop | H | H | OCH3 | 12 | oral |
| 5-MeO-DMT | CH3 | CH3 | H | H | OCH3 | 6 | par |
| psilocin | CH3 | CH3 | H | OH | H | 122 | oral |
| CZ-74 | C2H5 | C2H5 | H | OH | H | 152 | oral |
| 5-hydroxytryptamine (serotonin) | H | H | H | H | OH | 1003 | oral |
| bufotenine | CH3 | CH3 | H | H | OH | 164 | par |
| IT-290 | H | H | CH3 | H | H | 30 | oral |
| 4-hydroxy-alfa-methyl-tryptamine | H | H | CH3 | OH | H | 203 | oral |
| MP-809 | H | H | CH3 | H | CH3 | 605 | oral |
| 5-fluoro-alfa-methyl-tryptamine | H | H | CH3 | H | F | 256 | oral |
| 5-methoxy-alfa-methyl-tryptamine | H | H | CH3 | H | OCH3 | 3 | oral |
| 4-hydroxy-diisopropyl-tryptamine | i-prop | i-prop | H | OH | H | 126 | oral |
| 4-hydroxy-N-isopropyl, N-methyl-tryptamine |
i-prop | CH3 | H | OH | H | 66 | oral |
| N-t-butyl-tryptamine | H | t-butylH | H | H | ? | 7 | par? |
| 3-(2-(2,5-dimethylpyrrolyl) ethyl)-indole |
H | H | H | ? | ? | ? | ? |
| 5-alfa-DMT | CH3 | CH3 | CH3 | H | H | ? | ? |
1 Autonomic symptoms; little central activity.
2 The phosphate esters are psilocybin and CEY-19, respectively; both are stoichiometrically equivalent to the 4-hydroxy isomers.
3 Cardiovascular and autonomic symptoms; little central activity.
4 A pressor amine rather than a hallucinogen in man.
5 An antidepressant rather than a hallucinogen in man.
6 Based on anonymous reports in the lay press. No clinical studies have been published.
7 No oral activity with doses up to 20 mg, may be parenterally active.
Tryptamine derivatives and beta-carbolines have been detected as endogenous metabolites in mammals, including humans. Methyl transferases that catalyze the synthesis of tryptamines, including DMT, 5-MeO-DMT and bufotenine, are found in human lung, brain, cerebrospinal fluid, liver and heart (McKenna & Towers [1984]). In the pineal gland MAO is the primary inactivation pathway of serotonin, a neurotransmitter synthesized from the amino acid tryptophan. If MAO is blocked by harmine, harmaline or other MAO inhibitors serotonin can be converted by the methyltransferase enzymes HIOMT and INMT into psychedelic tryptamines (5-HT -(HIOMT)-> 5-MeOT -(2*INMT)-> 5-MeO-DMT).
So, ingesting l-tryptophan to increase serotonin levels, a candy bar to increase the amount of tryptophan getting to your brain and natural plant material containing 25-50 mg harmine/harmaline to block MAO, all at the same time, might cause your pineal gland to synthesize substantial amounts of 5-MeO-DMT (Most [1986]). This is extremely dangerous for persons with existing amine imbalance or schizophrenia. For normal, healthy people possible consequences are bad.
A potent inhibitor of INMT, which is a necessary enzyme for the synthesis of DMT and 5-MeO-DMT, is found in particularly high concentrations in the pineal gland. A bypassing or inhibition of the synthesis of this inhibitor might be responsible for trances and other psychedelic states achieved "without drugs" (Strassman [1990]). See Strassman's article for more information and speculation about the pineal gland.